Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Artesunate/pyronaridine - Medicines for Malaria Venture/Shin Poong Pharmaceutical

Drug Profile

Artesunate/pyronaridine - Medicines for Malaria Venture/Shin Poong Pharmaceutical

Alternative Names: M-PA01; PANDA; Pyramax; Pyronaridine/artesunate

Latest Information Update: 28 May 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Medicines for Malaria Venture; Shin Poong Pharmaceutical
  • Class Antimalarials; Naphthyridines; Peroxides; Sesquiterpenes; Small molecules
  • Mechanism of Action Free radical stimulants; Hemozoin inhibitors; Sarcoplasmic reticulum calcium-transporting ATPase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Malaria

Most Recent Events

  • 28 May 2019 No recent reports of development identified for phase-I development in Malaria(In volunteers) in Switzerland (PO, Tablet)
  • 04 Feb 2019 Chemical structure information added
  • 03 Oct 2018 Phase-II clinical trials in Malaria in Gambia, Zambia (PO) (NCT03814616)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top